Transcat(TRNS) - 2025 Q4 - Annual Results

Revenue Performance - Consolidated revenue for Q4 FY2025 was $77.1 million, an increase of 8.8% compared to Q4 FY2024[10] - Full fiscal year 2025 revenue reached $278.4 million, up 7.3% from $259.5 million in FY2024[20] - Total revenue for the fourth quarter ended March 29, 2025, was $77.134 million, a 8.4% increase from $70.913 million in the same quarter of the previous year[35] - Service revenue increased by 11.3% to $52.0 million in Q4 FY2025, driven by double-digit growth in the Calibration business[15] - Service revenue reached $52.010 million, up 11.6% from $46.732 million year-over-year, while distribution sales increased by 3.9% to $25.124 million[35] - Total revenue for Fiscal 2025 was $278,421 million, up 7.3% from $259,481 million in Fiscal 2024[49] Profitability Metrics - Adjusted EBITDA for Q4 FY2025 was $12.7 million, reflecting a 9.1% increase driven by strength in the Calibration business[12] - Gross profit for the fiscal year ended March 29, 2025, was $89.453 million, representing a 6.5% increase compared to $83.806 million in the prior year[35] - Adjusted EBITDA for the fiscal year 2025 reached $39,732,000, compared to $38,613,000 in fiscal 2024, indicating a year-over-year increase of 2.9%[41] - The service segment adjusted EBITDA for fiscal 2025 was $28,694,000, compared to $27,750,000 in fiscal 2024, representing a growth of 3.4%[41] - The distribution segment adjusted EBITDA for fiscal 2025 was $11,038,000, a decrease from $10,863,000 in fiscal 2024, indicating a decline of 1.6%[41] Net Income and Earnings Per Share - Net income for Q4 FY2025 decreased to $4.5 million, down 35.2% from $6.9 million in Q4 FY2024[9] - Net income for the fiscal year ended March 29, 2025, was $14,515,000, an increase of 6.35% from $13,647,000 in the previous year[39] - Adjusted diluted earnings per share for the fiscal year was $1.57, compared to $1.63 in the previous year, reflecting a decrease of 3.7%[35] - Fiscal 2025 net income reached $14,515 million, a significant increase from $13,647 million in Fiscal 2024, representing a year-over-year growth of 6.3%[45] - Diluted earnings per share (EPS) for Fiscal 2025 was $1.57, up from $1.63 in Fiscal 2024, while adjusted diluted EPS increased to $2.29 from $2.36[45] Expenses and Liabilities - Operating expenses increased by 27.9% to $19.0 million in Q4 FY2025, influenced by expenses from acquired businesses[11] - General and administrative expenses increased by 39.7% in Q4 of Fiscal 2025, totaling $9,733 million compared to $6,965 million in Q4 of Fiscal 2024[47] - Current liabilities slightly increased to $34.037 million from $33.499 million year-over-year, showing a stable financial position[37] Cash Flow and Investments - Net cash provided by operating activities increased to $38,985,000, up from $32,616,000, reflecting a growth of 19.5%[39] - Cash used in investing activities significantly rose to $84,000,000, compared to $41,672,000 in the prior year, marking a 101.5% increase[39] - The company reported a substantial business acquisition net cash outflow of $87,436,000 in fiscal 2025, compared to $12,859,000 in fiscal 2024[39] - Total cash and cash equivalents at the end of the period decreased to $1,517,000 from $19,646,000, reflecting a decline of 92.3%[39] Debt and Financial Position - Total debt increased to $32.7 million as of March 29, 2025, compared to $4.2 million on March 30, 2024[23] - The company reported a leverage ratio of 0.78 on March 29, 2025, indicating a strong balance sheet[24] Strategic Outlook - Management expects to return to high single-digit organic revenue growth as macro-trends normalize[7] - The company plans to expand its addressable calibration market through acquisitions and capability investments, aiming for organic sales growth[31] - Transcat's strategy includes leveraging its strong brand and unique value proposition to drive growth in highly regulated industries, particularly in Life Sciences[31]